Physician profile
Leonel Gras
NPI 1841288446
$3,099.67
in general payments reported to CMS, 2019-2025
23 companies · $711 in 2025
The $711 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $881 · 2022: $270 · 2023: $678 · 2024: $559 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.42 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $529.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $413.53 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $323.97 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $295.28 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $231.66 | 2023-2025 | Veozah |
| Amarin Pharma, INC. | $187.68 | 2021-2022 | |
| Pfizer INC. | $153.30 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $145.71 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.69 | 2021-2025 | |
| Amgen INC. | $136.64 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.76 | 2021-2025 | Jardiance |
| Abbvie INC. | $80.50 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $71.47 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $53.55 | 2025 | Airsupra |
| Shield Therapeutics INC | $38.09 | 2023 | Accrufer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $37.04 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.16 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $30.31 | 2021 | |
| Boston Scientific Corporation | $23.24 | 2021 | |
| Esperion Therapeutics, INC. | $19.80 | 2025 | Nexletol |
| Abbott Laboratories | $18.96 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.87 | 2023 | Nuzyra |
| Redhill Biopharma INC. | $16.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonel Gras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.